Effect of Probiotics on Endurance Athletes' Microbiome at Rest and Post-race

NCT ID: NCT05615961

Last Updated: 2022-11-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

70 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-01

Study Completion Date

2022-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is intended to investigate the use of probiotics (LAB4 probiotics, Cultech, Port Talbot, Wales, UK) and the effect this has on gastrointestinal symptoms experienced during elite long-distance triathlon (ironman) competition, as well as the composition of the gut bacteria in the athlete.

Long-distance triathlon events frequently induce gastrointestinal discomfort due to the duration of the event (8-17 hours), the intensity of the exercise and the ingestion of large amounts of sugars throughout the event.

Data will be collected from athletes participating at the Kona ironman World-championships. Participants will supplement with either probiotic tablet, or placebo (sugar-pill) for 4-weeks prior to competition.

Athletes will be both male and female age-group athletes from any qualifying age category (age categories are as follows: 18-24; 25-29; 30-34; 35-39; 40-44; 45-49; 50-54; 55-59; 60-64; 65-69; 70-74; 75-79; 80-84).

The main investigation of the study will be the occurence/frequency/severity of gastrointestinal symptoms during training and competition between groups.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will recruit ironman triathletes who have qualified for the Kona ironman World-championships in Hawaii. Participants will be allocated into either probiotic (Lab4 Probiotics, Cultech, Port Talbot, Wales, UK) or placebo (Maltodextrin) groups, in a double-blind fashion (Blinded by supplement supplier).

Those recruited into the study will have their training load and gut symptoms monitored for 8-weeks prior to competition via the completion of online questionnaires (previously validated).

Four-weeks prior to competition participants will provide a stool sample for microbiome analysis, they will then proceed to supplement with probiotic or placebo for 4-weeks. 24-h prior to competition they will provide a stool sample as well as providing a sample from the first bowel movement post-race, which will be used for microbiome analysis.

Data will be collected for pre-race and raceday nutrition, as well as outcome measures for raceday performance and gastroitestinal symptoms experienced, again via online questionnaire.

Stool samples will be analysed by an independent laboratory that specialises in microbiome analysis.

Primary outcome measures will be the composition of the gut bacteria and the metabolites (substances produced) of the gut bacteria at baseline, pre-race and post-race. As well as the occurrence (frequency, duration, severity) of gastrointestinal symptoms during training and competition.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gut Microbiome Gut Microbiota Aerobic Exercise Gastrointestinal Tract Irritation Athletes Probiotics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Participants are assigned into either supplement or placebo intervention groups, in a pair-matched, double-blind, placebo controlled manner.
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors
The study has been blinded by an impartial third party from the company that has provided both the probiotic supplements and the placebo capsules.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Probiotic Supplementation Arm

This group will receive the probiotic supplement for 4-weeks prior to their ironman race performance.

Group Type EXPERIMENTAL

Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)

Intervention Type DIETARY_SUPPLEMENT

The intervention is a unique blend of probiotic cultures from a well-established manufacturer.

Placebo Arm

This group will receive the placebo capsules for 4-weeks prior to their ironman race performance.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DIETARY_SUPPLEMENT

Placebo Tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Probiotics (Lab4 probiotics, Cultech, Port Talbot, Wales, UK)

The intervention is a unique blend of probiotic cultures from a well-established manufacturer.

Intervention Type DIETARY_SUPPLEMENT

Placebo

Placebo Tablets

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lab4 Probiotics, Cultech, Port Talbot, Wales, UK

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18-85
* Qualification for the Kona Ironman World-championships in Hawaii

Exclusion Criteria

* Have a current musculoskeletal injury.

* Currently unwell with cold or flu
* Have been told they have liver disease
* Have gastric Ulcer or other gastric/stomach problems
* Have a condition/disease of the Gut/bowel.
* Have diagnosed uncontrolled asthma
* Have kidney problems
* Have a chronic connective tissue disorder
* Have suffered cerebrovascular disease such as a stroke
* Are taking balcofen, methotrexate, tacrolimus and voriconazole, beta-blockers or diuretics drugs
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Georgia Southern University

OTHER

Sponsor Role collaborator

University of Illinois at Chicago

OTHER

Sponsor Role collaborator

Liverpool John Moores University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Liverpool John Moores University

Liverpool, Merseyside, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

021/SPS/051

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Multistrain Probiotic for Functional Constipation
NCT01618617 UNKNOWN PHASE2/PHASE3